SABCS 2025

Important new data for young breast cancer patients

Where is the future of SERDs in MBC?

Patients contribution is essential

ALTTO trial outcome according to endocrine therapy

AI based prognostic test

Giredestrant will replace current adjuvant therapy

SERDs in early breast cancer - the new era has begun?

Therapy optimization: Endocrine approaches in…

Surgery remains soc in low risk EBC

Revolution in adjuvant endocrine therapy?

SERDs now in adjuvant therapy

Optimized endocrine therapy for premenopausal patients

ctDNA analysis could optimize the approach in HER2+

Significant innovations in early and metastatic HER2+…

Quality of live data DB11

Safety data DB11

Olaparib neoadjuvant with high PCR rates

In addition to pCR, ctDNA is prognostically relevant…

Platinum adjuvant in TNBC

Carboplatino nel contesto adiuvante del TNBC

Risultati dello studio ALTTO in base alla terapia…

Otimização da terapia: abordagens endócrinas em…

La chirurgia rimane lo standard di cura nei casi di…

El análisis del ADN libre circulante podría optimizar…

Palbociclib likely delays CNS progression

Biomarker and clinical subgroup analysis of evERA…

Updated results of VIKTORIA-1

The significance of SG is more clearly defined

Elacestrant is a good combination partner for HR+ HER2+…

ASCENT-07 a negative trial

Phase 2 combination of elacestrant with everolimus or…

Make a hot tumor out of a cold tumor

No improvement over standard therapy

Triple-positive MBC: less chemotherapy, more endocrine…

Traditional chemotherapy should not be forgotten as…

Chemotherapy-free treatment: a promising therapeutic…

Monitoring of ILD

ctDNA Dynamics as a biomarker of response

Significant innovations in early and metastatic HER2+…

Maintenance therapy HER2+ Tucatinib as a new option

New evidence for oral SERDs

CDK4/6 inhibitor + endocrine therapy remains the…

Tucatinib, un nouveau SERD dans le cadre d'un…

Risultati aggiornati di VIKTORIA-1

Jeszcze nie czas na rezygnację z tradycyjnej…

La dinamica del ctDNA come biomarcatore di risposta

Résultats actualisés de VIKTORIA-1

Sem melhorias em relação à terapia padrão

Nuove prove a favore dei SERD orali